Niagen Bioscience, Inc. (NAGE)

Niagen Bioscience Stock Forecast

Stock Price Forecast

According to 5 analysts polled by S&P Global, Niagen Bioscience stock has a consensus rating of "Strong Buy" and an average price target of $12.6. The average 1-year stock price forecast is 250.00% higher than the current stock price, while the lowest is $10 (+177.78%) and the highest is $18 (+400.00%).

Price Target: $12.6 (+250.00%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$10	$12.6	$12	$18
Change	+177.78%	+250.00%	+233.33%	+400.00%

Analyst Ratings

The average analyst rating for Niagen Bioscience stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Dec '25	Jan '26	Feb '26	Mar '26	Apr '26	May '26
Strong Buy	3	3	3	3	3	3
Buy	0	0	0	0	0	0
Hold	0	0	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	3	3	3	3	3	3

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Raghuram Selvaraju HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Maintains $12 → $11	Strong Buy	Maintains	$12 → $11	+205.56%	May 11, 2026
Susan Anderson Canaccord Genuity	Canaccord Genuity	Strong Buy Maintains $13 → $10	Strong Buy	Maintains	$13 → $10	+177.78%	May 5, 2026
Susan Anderson Canaccord Genuity	Canaccord Genuity	Strong Buy Maintains $13	Strong Buy	Maintains	$13	+261.11%	Mar 31, 2026
Susan Anderson Canaccord Genuity	Canaccord Genuity	Strong Buy Maintains $14 → $13	Strong Buy	Maintains	$14 → $13	+261.11%	Mar 5, 2026
Susan Anderson Canaccord Genuity	Canaccord Genuity	Strong Buy Maintains $16 → $14	Strong Buy	Maintains	$16 → $14	+288.89%	Nov 5, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

145.13M

Increased by 12.14%

from 129.42M

Revenue Next Year

170.24M

Increased by 17.30%

from 145.13M

EPS This Year

0.24

Increased by 18.32%

from 0.20

EPS Next Year

0.31

Increased by 32.54%

from 0.24

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	67.45M	72.05M	83.57M	99.60M	129.42M	145.13M	170.24M
Revenue Growth	13.83%	6.82%	15.99%	19.18%	29.95%	12.14%	17.30%
EPS	-0.40	-0.24	-0.07	0.11	0.20	0.24	0.31
EPS Growth	-	-	-	-	81.82%	18.32%	32.54%
Forward PE	-	-	-	-	-	15.21	11.48
No. Analysts	-	-	-	-	-	7	6

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2026	2027	2028
High	151.9M	182.6M
Avg	145.1M	170.2M
Low	136.5M	156.8M

Revenue Growth

Revenue Growth	2026	2027	2028
High	17.3%	25.8%
Avg	12.1%	17.3%
Low	5.5%	8.0%

EPS Forecast

EPS	2026	2027	2028
High	0.29	0.38
Avg	0.24	0.31
Low	0.18	0.25

EPS Growth

EPS Growth	2026	2027	2028
High	47.0%	59.7%
Avg	18.3%	32.5%
Low	-11.8%	3.5%

Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.